• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌活检阴性后的检测风险因素:一种新的多变量纵向方法。

Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach.

机构信息

Department of Pathology, University of Illinois at Chicago, Chicago, IL 60612, USA.

出版信息

J Clin Oncol. 2010 Apr 1;28(10):1714-20. doi: 10.1200/JCO.2008.20.3422. Epub 2010 Feb 22.

DOI:10.1200/JCO.2008.20.3422
PMID:20177031
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2849765/
Abstract

PURPOSE

To introduce a novel approach for the time-dependent quantification of risk factors for prostate cancer (PCa) detection after an initial negative biopsy.

PATIENTS AND METHODS

Data for 1,871 men with initial negative biopsies and at least one follow-up biopsy were available. Piecewise exponential regression models were developed to quantify hazard ratios (HRs) and define cumulative incidence curves for PCa detection for subgroups with specific patterns of risk factors over time. Factors evaluated included age, race, serum prostate-specific antigen (PSA) concentration, PSA slope, digital rectal examination, dysplastic glands or prostatitis on biopsy, ultrasound gland volume, urinary symptoms, and number of negative biopsies.

RESULTS

Four hundred sixty-five men had PCa detected, after a mean follow-up time of 2.8 years. All of the factors were independent predictors of PCa detection except for PSA slope, as a result of its correlation with time-dependent PSA level, and race. PSA (HR = 3.90 for > 10 v 2.5 to 3.9 ng/mL), high-grade prostatic intraepithelial neoplasia/atypical glands (HR = 2.97), gland volume (HR = 0.39 for > 50 v < 25 mL), and number of repeat biopsies (HR = 0.36 for two v zero repeat biopsies) were the strongest predictors. Men with high-risk versus low-risk event histories had a 20-fold difference in PCa detection over 5 years.

CONCLUSION

Piecewise exponential models provide an approach to longitudinal analysis of PCa risk that allows clinicians to see the interplay of risk factors as they unfold over time for individual patients. With these models, it is possible to identify distinct subpopulations with dramatically different needs for monitoring and repeat biopsy.

摘要

目的

介绍一种新方法,用于对初始阴性活检后前列腺癌(PCa)检测的危险因素进行时依性定量分析。

患者和方法

我们获得了 1871 名初始阴性活检且至少有一次后续活检的男性数据。我们开发了分段指数回归模型,以量化风险比(HR),并为具有特定危险因素模式的亚组定义 PCa 检测的累积发生率曲线。评估的因素包括年龄、种族、血清前列腺特异性抗原(PSA)浓度、PSA 斜率、直肠指检、活检时出现发育不良腺体或前列腺炎、超声腺体体积、尿路症状和阴性活检次数。

结果

465 名男性在平均 2.8 年的随访后被检出患有 PCa。除了 PSA 斜率外,所有因素都是 PCa 检测的独立预测因子,这是由于 PSA 斜率与时间依赖性 PSA 水平相关,以及与种族相关。PSA(>10 v 2.5 至 3.9 ng/mL 的 HR = 3.90)、高级别前列腺上皮内瘤变/非典型腺体(HR = 2.97)、腺体体积(>50 v <25 mL 的 HR = 0.39)和重复活检次数(两次重复活检 v 零次重复活检的 HR = 0.36)是最强的预测因子。高危事件史与低危事件史男性在 5 年内 PCa 检出率相差 20 倍。

结论

分段指数模型为 PCa 风险的纵向分析提供了一种方法,使临床医生能够随着时间的推移观察个体患者的危险因素相互作用。有了这些模型,就有可能识别出具有截然不同的监测和重复活检需求的不同亚群。

相似文献

1
Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach.前列腺癌活检阴性后的检测风险因素:一种新的多变量纵向方法。
J Clin Oncol. 2010 Apr 1;28(10):1714-20. doi: 10.1200/JCO.2008.20.3422. Epub 2010 Feb 22.
2
Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.在芬兰前列腺癌筛查试验中,最初血清前列腺特异性抗原(PSA)浓度升高的男性中,组织学炎症与随后发生前列腺癌的风险。
BJU Int. 2013 Oct;112(6):735-41. doi: 10.1111/bju.12153. Epub 2013 Jun 7.
3
Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.初始广泛阴性活检后重复活检和前列腺癌检出的风险:来自前瞻性试验的纵向随访。
BJU Int. 2013 May;111(6):988-96. doi: 10.1111/j.1464-410X.2012.11607.x. Epub 2013 Mar 4.
4
Is race a positive predictor of cancer on repeat prostate biopsy?在重复前列腺活检中,种族是癌症的一个正向预测指标吗?
J Urol. 2006 Sep;176(3):1114-7. doi: 10.1016/j.juro.2006.04.041.
5
Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.用于辅助疑似前列腺癌患者诊断方法选择的活检规避预测工具的创建与内部验证。
Urol Oncol. 2017 Oct;35(10):604.e17-604.e24. doi: 10.1016/j.urolonc.2017.06.044. Epub 2017 Aug 7.
6
Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy.经直肠超声引导下重复系统前列腺穿刺活检中前列腺癌的预测因素
Int J Urol. 2003 Feb;10(2):68-71. doi: 10.1046/j.1442-2042.2003.00579.x.
7
A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.在首次、二次和三次重复前列腺活检中,总前列腺特异性抗原、游离前列腺特异性抗原百分比、前列腺特异性抗原速度和尿前列腺癌基因 3 的比较性能分析。
BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.
8
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.前列腺特异性抗原(PSA)同工型 p2PSA 显著提高了总 PSA 为 2.0-10ng/ml 的患者初始扩展前列腺活检中前列腺癌的预测能力:一项临床环境中前瞻性研究的结果。
Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5.
9
Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies.前列腺穿刺活检阴性结果中增殖性炎性萎缩的临床意义
Prostate. 2016 Dec;76(16):1501-1506. doi: 10.1002/pros.23234. Epub 2016 Jul 12.
10
The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.初次饱和穿刺活检时高级别前列腺上皮内瘤变及可疑癌的非典型腺泡的发生率,以及后续的癌症风险。
BJU Int. 2007 Apr;99(4):770-4. doi: 10.1111/j.1464-410X.2006.06728.x. Epub 2007 Jan 16.

引用本文的文献

1
Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.可改变的风险因素与初始前列腺活检阴性的男性后续致命性前列腺癌相关。
Br J Cancer. 2023 Dec;129(12):1988-2002. doi: 10.1038/s41416-023-02472-y. Epub 2023 Oct 28.
2
Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result.初始非恶性活检结果后标准化的前列腺癌发病率和死亡率。
BJU Int. 2023 Aug;132(2):181-187. doi: 10.1111/bju.15997. Epub 2023 Mar 14.
3
MR conditional prostate intervention systems and actuations review.磁共振引导下前列腺介入治疗系统及作用机制研究进展
Proc Inst Mech Eng H. 2023 Jan;237(1):18-34. doi: 10.1177/09544119221136169. Epub 2022 Dec 1.
4
Clinical strategy of repeat biopsy in patients with atypical small acinar proliferation (ASAP).不典型细支气管肺泡增生(ASAP)患者重复活检的临床策略。
Sci Rep. 2021 Nov 30;11(1):23143. doi: 10.1038/s41598-021-02172-8.
5
Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood.按种族和民族划分的前列腺癌差异:从核苷酸到邻里环境。
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a030387. doi: 10.1101/cshperspect.a030387.
6
Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.单细胞基因组学在前列腺癌诊断评估中的应用。
Cancer Res. 2018 Jan 15;78(2):348-358. doi: 10.1158/0008-5472.CAN-17-1138. Epub 2017 Nov 27.
7
Safety and Feasibility of Direct Magnetic Resonance Imaging-guided Transperineal Prostate Biopsy Using a Novel Magnetic Resonance Imaging-safe Robotic Device.使用新型磁共振成像安全机器人设备进行直接磁共振成像引导下经会阴前列腺活检的安全性和可行性
Urology. 2017 Nov;109:216-221. doi: 10.1016/j.urology.2017.07.010. Epub 2017 Jul 19.
8
The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population.非裔美国人种族对退伍军人人群重复前列腺活检中前列腺癌检测的影响。
Int Urol Nephrol. 2016 Dec;48(12):2015-2021. doi: 10.1007/s11255-016-1407-8. Epub 2016 Aug 31.
9
Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection.重复24针饱和前列腺穿刺活检分析:无症状组织学炎症与前列腺癌检测之间的负相关关系。
Oncol Lett. 2016 Aug;12(2):1132-1138. doi: 10.3892/ol.2016.4693. Epub 2016 Jun 9.
10
Prostate Cancer Diagnosis on Repeat Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling.良性病变的重复磁共振成像-经直肠超声融合活检前列腺癌诊断:重复采样建议。
J Urol. 2016 Jul;196(1):62-7. doi: 10.1016/j.juro.2016.02.066. Epub 2016 Feb 13.

本文引用的文献

1
Evidence for field cancerization of the prostate.前列腺场癌化的证据。
Prostate. 2009 Sep 15;69(13):1470-9. doi: 10.1002/pros.20983.
2
Quantifying the role of PSA screening in the US prostate cancer mortality decline.量化前列腺特异性抗原(PSA)筛查在美国前列腺癌死亡率下降中的作用。
Cancer Causes Control. 2008 Mar;19(2):175-81. doi: 10.1007/s10552-007-9083-8. Epub 2007 Nov 20.
3
High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates.
Urology. 2007 Oct;70(4):691-5. doi: 10.1016/j.urology.2007.05.017.
4
Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.在前列腺特异性抗原(PSA)时代,通过活检在医疗保险-监测、流行病学和最终结果(SEER)人群中检测前列腺癌。
J Natl Cancer Inst. 2007 Sep 19;99(18):1395-400. doi: 10.1093/jnci/djm119. Epub 2007 Sep 11.
5
Assessing individual risk for prostate cancer.评估前列腺癌的个体风险。
J Clin Oncol. 2007 Aug 20;25(24):3582-8. doi: 10.1200/JCO.2007.10.6450.
6
Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.使用前列腺特异性抗原速度对前列腺活检发现孤立性高级别前列腺上皮内瘤变的患者进行随访。
Urology. 2007 Jan;69(1):108-12. doi: 10.1016/j.urology.2006.09.040.
7
Development and external validation of an extended repeat biopsy nomogram.扩展重复活检列线图的开发与外部验证
J Urol. 2007 Feb;177(2):510-5. doi: 10.1016/j.juro.2006.09.025.
8
Atypical small acinar proliferation in the prostate: clinical significance in 2006.前列腺非典型小腺泡增生:2006年的临床意义
Arch Pathol Lab Med. 2006 Jul;130(7):952-7. doi: 10.5858/2006-130-952-ASAPIT.
9
Is chronic inflammatory change in the prostate the major cause of rising serum prostate-specific antigen in patients with clinical suspicion of prostate cancer?对于临床怀疑患有前列腺癌的患者,前列腺的慢性炎症变化是血清前列腺特异性抗原升高的主要原因吗?
Int J Urol. 2006 Feb;13(2):122-6. doi: 10.1111/j.1442-2042.2006.01244.x.
10
Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies.
Cancer. 2005 Nov 1;104(9):1911-7. doi: 10.1002/cncr.21420.